AR127584A1 - NOVEL COMPOUNDS - Google Patents

NOVEL COMPOUNDS

Info

Publication number
AR127584A1
AR127584A1 ARP220103036A ARP220103036A AR127584A1 AR 127584 A1 AR127584 A1 AR 127584A1 AR P220103036 A ARP220103036 A AR P220103036A AR P220103036 A ARP220103036 A AR P220103036A AR 127584 A1 AR127584 A1 AR 127584A1
Authority
AR
Argentina
Prior art keywords
salt
compound
formula
pharmaceutically acceptable
disease
Prior art date
Application number
ARP220103036A
Other languages
Spanish (es)
Inventor
David Cousin
Oscar Barba
Original Assignee
Sitryx Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sitryx Therapeutics Ltd filed Critical Sitryx Therapeutics Ltd
Publication of AR127584A1 publication Critical patent/AR127584A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a compuestos de fórmula (1a) y a su uso en el tratamiento o prevención de una enfermedad inflamatoria, una enfermedad asociada con una respuesta inmunitaria indeseable, cáncer, obesidad, una enfermedad diabética o un trastorno de la sangre, en donde RA, RB, RC y RD, X, Y¹, Y², Y³, Z¹, Z² y m son como se define en la presente. Reivindicación 61: Una composición farmacéutica que comprende un compuesto, sal y/o solvato aceptable desde el punto de vista farmacéutico de este, de acuerdo con una cualquiera de las reivindicaciones 1 a 60, y uno o más portadores o diluyentes aceptables desde el punto de vista farmacéutico. Reivindicación 65: Un método para tratar o prevenir una enfermedad, trastorno o afección asociada con la función de PK, en particular PKM2 y/o PKLR, que comprende administrar un compuesto, sal y/o solvato aceptable desde el punto de vista farmacéutico de este de acuerdo con una cualquiera de las reivindicaciones 1 a 60 o una composición farmacéutica de acuerdo con la reivindicación 61. Reivindicación 107: Un proceso para preparar un compuesto de fórmula (1a) como se describe en una cualquiera de las reivindicaciones 1 a 60, o una sal, tal como una sal y/o solvato aceptable desde el punto de vista farmacéutico de este, que comprende hacer reaccionar un compuesto de fórmula (2a-S); o una sal de este; con un compuesto de fórmula (3a-S); en donde RA, RB, RC, RD, Y¹, Y², Y³, Z¹, Z², X y m se definen de acuerdo con una cualquiera de las reivindicaciones 1 a 40, y LG² es un grupo saliente tal como halo (por ejemplo, cloro, bromo o yodo), OMs u OTs.The invention relates to compounds of formula (1a) and their use in the treatment or prevention of an inflammatory disease, a disease associated with an undesirable immune response, cancer, obesity, a diabetic disease or a blood disorder, where RA , RB, RC and RD, X, Y¹, Y², Y³, Z¹, Z² and m are as defined herein. Claim 61: A pharmaceutical composition comprising a pharmaceutically acceptable compound, salt and/or solvate thereof, according to any one of claims 1 to 60, and one or more pharmaceutically acceptable carriers or diluents. pharmaceutical view. Claim 65: A method of treating or preventing a disease, disorder or condition associated with the function of PK, in particular PKM2 and/or PKLR, comprising administering a pharmaceutically acceptable compound, salt and/or solvate thereof according to any one of claims 1 to 60 or a pharmaceutical composition according to claim 61. Claim 107: A process for preparing a compound of formula (1a) as described in any one of claims 1 to 60, or a salt, such as a pharmaceutically acceptable salt and/or solvate thereof, comprising reacting a compound of formula (2a-S); or a salt of this; with a compound of formula (3a-S); wherein RA, RB, RC, RD, Y¹, Y², Y³, Z¹, Z², , bromine or iodine), OMs or OTs.

ARP220103036A 2021-11-05 2022-11-04 NOVEL COMPOUNDS AR127584A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21206793 2021-11-05
EP21216843 2021-12-22
EP22177827 2022-06-08

Publications (1)

Publication Number Publication Date
AR127584A1 true AR127584A1 (en) 2024-02-07

Family

ID=84331339

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103036A AR127584A1 (en) 2021-11-05 2022-11-04 NOVEL COMPOUNDS

Country Status (3)

Country Link
AR (1) AR127584A1 (en)
TW (1) TW202325288A (en)
WO (1) WO2023079294A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070078172A1 (en) * 2005-06-16 2007-04-05 Jenrin Discovery Mao-b inhibitors useful for treating obesity
CN103833646A (en) * 2014-02-28 2014-06-04 广东工业大学 Fatty amino substituted quinazolinone derivative and preparation method and application thereof
JP2022520090A (en) 2019-02-13 2022-03-28 アジオス ファーマシューティカルズ， インコーポレイテッド Thieno [3,2-B] pyrrole [3,2-D] pyridadinone derivatives and their use as PKM2 derivatives for the treatment of cancer, obesity and diabetes-related disorders
US20220242850A1 (en) * 2019-07-30 2022-08-04 Janssen Pharmaceutica Nv Phthalazin-1-one derivatives useful as grk2 inhibitors
CN112156095A (en) * 2020-10-27 2021-01-01 兰州大学 M2 type pyruvate kinase small molecule activator and application thereof

Also Published As

Publication number Publication date
WO2023079294A1 (en) 2023-05-11
TW202325288A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
AR118856A2 (en) THERAPEUTIC COMPOUNDS
CO2022010460A2 (en) Substituted tricyclic compounds
AU2004249639B2 (en) Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them
CL2019002167A1 (en) Compound of formula (ic) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising said compound or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, and its use in the treatment of familial dysautonomia by improving the marn joint. (divisional application 201701823.)
JP7044392B2 (en) Compounds and methods for the treatment of malaria
CL2022001392A1 (en) Substituted tricyclic compounds
RU2017121906A (en) CONJUGATES OF CYSTEAMINE AND FATTY ACID AND THEIR APPLICATION AS AUTOFAGIA ACTIVATORS
RU2016101244A (en) NEW CONJUGATES OF ANALOGUES SS-1065 AND BIFUNCTIONAL LINKERS
AR046297A1 (en) DPP INHIBITORS - IV METHODS TO PREPARE THEM AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AS ACTIVE AGENTS
CA2962524A1 (en) (2-(1-h-indolyl)imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone useful for the treatment of cancer
AR059590A1 (en) HYDANTOIN-BASED QUINASE INHIBITORS
JP2017538689A5 (en)
AR048607A1 (en) DERIVATIVES (POLI) AMINOALQUILAMINO ACETAMIDE OF EPIPODOFILOTOXINA, PROCESS OF PREPARATION OF THE SAME AND ITS THERAPEUTIC APPLICATIONS AS ANTICANCEROS AGENTS
JP2016535732A5 (en)
CA2868002C (en) Antimicrobial agents
JP2017503753A5 (en)
AR035071A1 (en) COMPOUNDS FOR THE TREATMENT OF ENDOTELIAL DYSFUNCTION; METHOD FOR PRODUCING THESE PHARMACEUTICAL COMPOUNDS; USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
WO2010084798A1 (en) Tricyclic compound
CN106794174A (en) The compound for the treatment of cancer
AR114679A1 (en) HETEROCYCLIC FUNGICIDE COMPOUNDS
PE20212111A1 (en) CALPAIN MODULATORS AND THERAPEUTIC USES OF THE SAME
JP2020520955A5 (en)
AR127584A1 (en) NOVEL COMPOUNDS
AR040968A1 (en) BIFENYL CARBOXAMIDS REPLACED WITH N- ARIL PIPERIDINA, A METHOD FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION AND PREPARATION PROCESS
PE20230601A1 (en) PYRROLOPYRIMIDIMINES AS INHIBITORS OF THE COMPLEMENT SYSTEM